Literature DB >> 11916152

Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate.

N L Acan1, N Ozer.   

Abstract

Human erythrocyte pyruvate kinase was modified with bromopyruvate and the kinetic behavior of the modified enzyme was investigated. When the enzyme was modified with bromopyruvate in the absence of adenosine-5'-diphosphate, phosphoenolpyruvate or fructose-1,6-diphosphate the inactivation followed a pseudo first-order kinetics. The inactivation rate constant, ks, was 1.84 +/- 0.15 min(-1). Kd of the bromopyruvate-enzyme complex was 0.14 +/- 0.03 mM. The presence of adenosine-5'-diphosphate, phosphoenolpyruvate or fructose-1,6-diphosphate in the modification medium or the presence of fructose-1,6-diphosphate in the assay medium resulted in deviation of the inactivation kinetics from pseudo first-order. Phosphoenolpyruvate was better than adenosine-5'-diphosphate for protection against bromopyruvate modification whereas fructose-1,6-diphosphate was ineffective. The modified enzyme showed negative cooperativity in the presence of fructose-1,6-diphosphate whereas in the absence of it no activity was detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11916152     DOI: 10.1080/14756360109162395

Source DB:  PubMed          Journal:  J Enzyme Inhib        ISSN: 1026-5457


  6 in total

1.  Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.

Authors:  Muthusamy Thangaraju; Senthil K Karunakaran; Shiro Itagaki; Elangovan Gopal; Selvakumar Elangovan; Puttur D Prasad; Vadivel Ganapathy
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

Review 2.  3-Bromopyruvate: targets and outcomes.

Authors:  Maria C Shoshan
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

3.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Jean-Francois H Geschwind; Rani Kunjithapatham; Manon Buijs; Josephina A Vossen; Irina Tchernyshyov; Robert N Cole; Labiq H Syed; Pramod P Rao; Shinichi Ota; Mustafa Vali
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

4.  Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: Implication in designing of novel anticancer therapeutic strategies.

Authors:  Saveg Yadav; Shrish Kumar Pandey; Vinay Kumar Singh; Yugal Goel; Ajay Kumar; Sukh Mahendra Singh
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

Review 5.  Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment.

Authors:  Tengjiao Fan; Guohui Sun; Xiaodong Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

6.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.

Authors:  Kivanç Birsoy; Tim Wang; Richard Possemato; Omer H Yilmaz; Catherine E Koch; Walter W Chen; Amanda W Hutchins; Yetis Gultekin; Tim R Peterson; Jan E Carette; Thijn R Brummelkamp; Clary B Clish; David M Sabatini
Journal:  Nat Genet       Date:  2012-12-02       Impact factor: 38.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.